Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Using MRD as an endpoint in clinical trials

Hervé Avet-Loiseau • 14 Sep 2019
IMW 2019
Multiple Myeloma

Hervé Avet-Loiseau, MD, PhD, Cancer Research Center of Toulouse, Toulouse, France, outlines the potential benefits of using (measurable residual disease) MRD as an
an endpoint in myeloma treatment at the International Myeloma Workshop (IMW) 2019, Boston, MA.

More from Hervé Avet-Loiseau

2:11
Comparing MRD analysis methods
Hervé Avet-Loiseau • 14 Sep 2019
14:15
Working towards a cure for multiple myeloma
Brian Walker et al. • 27 Jan 2017
11:23
Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma
Bruno Paiva et al. • 27 Jan 2017
3:22
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
Hervé Avet-Loiseau • 30 Apr 2016

Related Videos

2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals